08/15/2022
From the Prostate Cancer Research Desk: Benefits of COVID-19 Vaccines, PSA Screening
In this roundup of recent prostate cancer research, data from the U.S. Veterans Health Administration yields insights into the benefits of COVID-19 vaccination and of PSA screening. COVID-19 vaccination protects patients with cancer against infection and death In case you needed another reason to get a COVID-19 vaccine or booster,. Read More
07/26/2022
Researchers Identify a New Subtype of Advanced Prostate Cancer
A PCF-funded study published in the prestigious journal Science has identified a new subtype of castration-resistant prostate cancer (CRPC). Understanding how genes and proteins “drive” this particular type of cancer may lead to new treatments. In the early stages, prostate cancer cells are driven by androgens (e.g., testosterone), which naturally. Read More
07/18/2022
Plant-Based Diets and Prostate Cancer
“Plant-based” foods are increasingly on the radar. You can grab a green juice at most chain coffee shops, a decent salad at airport restaurants, or a meat-free veggie burger at some locations of the major burger chains. And at many local grocery stores or farmers’ markets, you can purchase ingredients. Read More
06/28/2022
Highlights from the American Society of Clinical Oncology 2022 Annual Meeting, Part 2
The American Society of Clinical Oncology (ASCO) held its Annual Meeting in Chicago in early June. PCF Young Investigator Eugene Shenderov, MD, of Johns Hopkins, presented early results of a new immunotherapy agent in localized prostate cancer. Patients diagnosed with intermediate- and high-risk prostate cancer have treatment options such as. Read More
06/24/2022
Highlights from the American Society of Clinical Oncology 2022 Annual Meeting, Part 1
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest scientific meetings focused on cancer, where physicians, scientists, advocates, and industry partners share the latest developments in research and treatment. At the 2022 meeting held in Chicago this summer, there were multiple presentations on 177Lutetium-PSMA-617 (Lu-PSMA;. Read More
06/06/2022
Alternative Endpoints: Results that Potentially Accelerate Phase 3 Clinical Trials in Metastatic Hormone-Sensitive Prostate Cancer
Clinical trials can bring life-extending and potentially curative new treatments to patients with cancer. They play a vital role in determining the safety and efficacy of investigational treatments, generating data which the FDA requires for making decisions on whether a new therapy can be approved and enter widespread clinical practice.. Read More
05/18/2022
Metastatic Prostate Cancer: Don’t Accept Complacency!
“This is all we can do” is a phrase no cancer patient wants to hear, especially someone with metastatic disease. Medical oncologist and PCF-funded investigator Andrew Armstrong, M.D., M.Sc., hears those six words a lot – from patients who have come to see him at Duke University’s Cancer Center, a. Read More
05/02/2022
Research Update from AACR 2022, Part 2
Research Update from AACR 2022, Part 2 The American Association for Cancer Research Annual Meeting 2022 was held in New Orleans in April. Dr. Andrea Miyahira, PCF’s Director of Global Research and Scientific Communications, has identified key updates that were presented at the meeting. In Part 2, we highlight two. Read More
04/25/2022
Research Update from AACR 2022, Part 1: Spotlight on Immunotherapy
The American Association for Cancer Research Annual Meeting was held in New Orleans in April. Dr. Andrea Miyahira, PCF’s Director of Global Research and Scientific Communications, has identified key updates that were presented at the meeting. This week, we highlight two presentations on potential ways to optimize the use of. Read More
03/29/2022
Highlights of ASCO GU 2022, Part 2
Informing care for intermediate-risk cancer, a new imaging tracer, and understanding the effects of PSA screening recommendations Clinicians and researchers gathered last month at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) — some in-person in San Francisco, some tuning in virtually. Hundreds of presentations covered advances. Read More
- 1
- 2